Dentsply Sirona Announces Appointment of Dr. Dorothea Wenzel as New Board Member
Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, today announced that Dr. Dorothea Wenzel has been appointed to its Board of Directors.
Dr. Dorothea Wenzel, member of the Board of Directors at Dentsply Sirona.
Charlotte. DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that Dr. Dorothea Wenzel has been appointed to its Board of Directors (the “Board”), increasing the size of its Board from ten to eleven members. Dr. Wenzel has also been appointed as a member of the Audit and Finance Committee.
“On behalf of Dentsply Sirona and the Board of Directors, I am pleased to welcome Dr. Wenzel to Dentsply Sirona.” said Eric K. Brandt, Chairman of the Board. “Dr. Wenzel is a highly experienced executive with an impressive strategic, financial, and general management track record in the health care sector. Her expertise will enhance and broaden the Board’s international perspective as we continue to build and refresh our Board. We look forward to working with her to continue to shape the future of Dentsply Sirona and work to realize our vision advancing dentistry to improve oral health worldwide.“
Dr. Dorothea Wenzel served for Merck KGaA, Darmstadt, Germany, from June 2004 to August 2021, most recently since 2019 as Executive Vice President and Head of the Surface Solutions Business Unit. At Merck, KGaA, Darmstadt, Germany, she further held various Senior Management Positions in the Health Care Division of the DAX-listed company. Prior to joining Merck, Dr. Wenzel held a number of finance and business positions in the health care industry at AXA Krankenversicherung AG and Medvantis Holding AG and worked for several years as consultant and engagement manager at McKinsey & Comp. Dr. Wenzel was also a Member of the Staff of the Committee for the Sustainability of the Financing of the Social Security Systems of the Federal Ministry of Health (Germany). She holds a doctorate in Health Economics and a diploma in business & computer sciences from the Technical University of Darmstadt. Dr. Dorothea Wenzel is member of the supervisory board of Fresenius Medical Care AG & Co. KGaA and an independent director on the board of H. Lundbeck A/S.
Download Material
Whitepaper added to Download Queue
Already in collection
Dr. Dorothea Wenzel, member of the Board of Directors at Dentsply Sirona.
This information and any attachment thereto contains forward-looking information about Dentsply Sirona, Inc.'s financial results, guidance and estimates, business prospects, and products and services that involve substantial risks and uncertainties or other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You can identify these statements by the use of words such as "may," "could," "estimate," "will," "believe," "anticipate," "think," "intend," "expect," "project," "plan," "target," "forecast", and similar words and expressions which identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and involve known and unknown risks and uncertainties, and other factors. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental product and services, pricing, future sales volume of the Company's products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, acquisitions and affiliations, readers are urged to carefully review and consider various disclosures made by the Company in its Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements contained in this document or the attachments to reflect new information or future events or developments after the date any such statement is made.